Information Provided By: 
Fly News Breaks for March 26, 2015
ICPT
Mar 26, 2015 | 14:45 EDT
Citigroup said Conatus Phase II trial of emricasn met the primary endpoint of reducing ALT but safety concerns continue to linger given it is a pancaspase inhibitor. Citigroup's anlyst is not clear so far if there was a reduction NAS and fibrosis of the same magnitude demonstrated by Intercept's (ICPT) OCA. The firm believes the market is large enough for several players and continues to like the risk/reward profile of Intercept. Intercept is rated Buy with a $475 price target.
News For ICPT From the Last 2 Days
There are no results for your query ICPT
